Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARS PharmaceuticalsSPRY +1.51%28 10-Year ROIIC % is 912.10 as of Dec. 2025. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,100 Biotechnology companies, ARS Pharmaceuticals ranks better than 95.82% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
ARS Pharmaceuticals does not have enough data to calculate 10-Year ROIIC %.
ARS Pharmaceuticals (NAS:SPRY) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ARS Pharmaceuticals 10-Year ROIIC % Related Terms
ARS Pharmaceuticals 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRY vs ALLO, CBIO, IMMX: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, ARS Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's 10-Year ROIIC % falls into.
ARS Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -179.358276 (Dec. 2025) - (Dec. 2015) )
/
( 44.718 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ARS Pharmaceuticals (SPRY) has a 10-Year ROIIC % of 912.10 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on ARS Pharmaceuticals and its competitors. According to the industry distribution chart, ARS Pharmaceuticals ranks #46 out of 1100 companies in the Biotechnology industry, placing it in the top 4.2%.
Is ARS Pharmaceuticals' 10-Year ROIIC % too high?
ARS Pharmaceuticals' current 10-Year ROIIC % is 912.10. Based on the distribution chart, ARS Pharmaceuticals ranks #46 out of 1100 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' 10-Year ROIIC % compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #46 out of 1100 companies for 10-Year ROIIC %. This places ARS Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on ARS Pharmaceuticals and its competitors. ARS Pharmaceuticals's current 10-Year ROIIC % is 912.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current 10-Year ROIIC % of 912.10. The current 10-Year ROIIC % is 912.10. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current 10-Year ROIIC % is 912.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score
Get the complete analysis for SPRY
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
